A large cohort of patients around the world diagnosed with myelofibrosis (aka bone marrow cancer) will soon be able to access a new treatment which has already shown to be effective in a small group of patients undergoing treatment of PXS-5505 in Phase 2 clinical trials. Myelofibrosis is a rare cancer of the bone marrow
Read More
There is an urgent need for better treatment for myelodysplastic syndrome (MDS), a type of blood cancer, and new research published in prestigious scientific journal Nature Communications suggests a breakthrough could be coming. Researchers at the University of Heidelberg in Germany have reported results claimed to be “the best we have ever observed in our
Read More
Aussies are some of the most enthusiastic adopters of new clinical drugs. In 2019, 95,000 of us participated in nearly 2,000 clinical trials where Australia is home to many of the world’s leading scientists. In keeping with that, clinical stage biotech company Pharmaxis (ASX: PXS) has a thriving drug development pipeline set to report clinical
Read More
Having delivered impressive interim trial data from their Phase 2 clinical trials for a treatment targeting incurable bone marrow cancer, the US Food & Drug Administration (FDA) could soon be the next stop for biopharmaceuticals company Pharmaxis (ASX: PXS) fresh off their poster presentation at the American Society of Hematology (ASH) conference. Hosted in New
Read More